Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-10-27FDA Approved: CARBIDOPA AND LEVODOPA — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for carbidopa-levodopa (Zydus Pharmaceuticals USA Inc.). The drug is used to treat Parkinson's d…
-
FDA approval · 2016-10-13FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for pramipexole dihydrochloride from Torrent Pharmaceuticals Limited.
-
FDA approval · 2016-09-15FDA Approved: DUOPA — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for DUOPA (carbidopa and levodopa) from AbbVie Inc.
-
FDA approval · 2016-06-24FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for Pramipexole dihydrochloride from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2016-06-24FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved Macleods Pharmaceuticals' pramipexole dihydrochloride as an original generic application, enabling a generic version of pramipe…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-06-03FDA Approved: NEUPRO — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for NEUPRO (rotigotine) submitted by UCB, Inc.
-
FDA approval · 2016-06-03FDA Approved: CARBIDOPA AND LEVODOPA — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Carbidopa and Levodopa from Zydus Pharmaceuticals USA Inc., broadening the product's approva…
-
FDA approval · 2016-05-31FDA Approved: AMANTADINE HYDROCHLORIDE — Original Application (Zydus Lifesciences Limited)
FDA approved amantadine hydrochloride as a generic product under an original application from Zydus Lifesciences Limited.
-
FDA approval · 2016-05-11FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (ScieGen Pharmaceuticals Inc)
The FDA approved a supplemental application for pramipexole dihydrochloride submitted by ScieGen Pharmaceuticals Inc.
-
FDA approval · 2016-05-10FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approves Glenmark’s supplemental application for pramipexole dihydrochloride, authorizing a generic version of the drug.
-
FDA approval · 2016-04-29FDA Approved: NUPLAZID — Original Application (Acadia Pharmaceuticals Inc.)
The FDA approved Nuplazid (pimavanserin tartrate) from Acadia Pharmaceuticals in its original NDA, for the treatment of hallucinations and d…
-
FDA approval · 2016-04-28FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for pramipexole dihydrochloride from Aurobindo Pharma Limited. The drug is indicated for the treatme…
-
FDA approval · 2016-03-15FDA Approved: RASAGILINE — Original Application (Alvogen, Inc.)
FDA approves an original generic application for rasagiline, a monoamine oxidase-B inhibitor indicated for Parkinson's disease, from Alvogen…
-
FDA approval · 2016-03-14FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for pramipexole dihydrochloride from Alembic Pharmaceuticals Limited. This action approves a sup…
-
FDA approval · 2016-02-25FDA Approved: CARBIDOPA, LEVODOPA, AND ENTACAPONE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for the carbidopa/levodopa/entacapone combination by Sandoz Inc.
-
FDA approval · 2016-02-22FDA Approved: CARBIDOPA, LEVODOPA, AND ENTACAPONE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for the combination product carbidopa, levodopa, and entacapone (Sandoz), expanding the regulatory a…
-
FDA approval · 2016-02-18FDA Approved: CARBIDOPA, LEVODOPA, AND ENTACAPONE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for Sandoz Inc.'s carbidopa/levodopa/entacapone product. It is used to treat Parkinson's disease…
-
FDA approval · 2016-02-17FDA Approved: CARBIDOPA — Original Application (Edenbridge Pharmaceuticals LLC.)
FDA approved Edenbridge Pharmaceuticals LLC's Original Application for a generic carbidopa product. The drug is used to treat Parkinson dise…
-
FDA approval · 2016-02-15FDA Approved: CARBIDOPA AND LEVODOPA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental Abbreviated New Drug Application for Teva's generic carbidopa/levodopa. The product is a standard treatment for …
-
FDA approval · 2016-01-29FDA Approved: CARBIDOPA, LEVODOPA, AND ENTACAPONE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for the carbidopa/levodopa/entacapone combination from Sandoz Inc.
-
FDA approval · 2016-01-26FDA Approved: DUOPA — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for DUOPA (carbidopa and levodopa) submitted by AbbVie Inc.
-
FDA approval · 2016-01-10FDA Approved: ROPINIROLE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for ropinirole submitted by Alembic Pharmaceuticals Limited (ANDA 202786).
-
FDA approval · 2015-12-21FDA Approved: DUOPA — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for DUOPA (carbidopa and levodopa) submitted by AbbVie.
-
FDA approval · 2015-12-14FDA Approved: CARBIDOPA AND LEVODOPA — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Carbidopa and Levodopa from Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2015-12-11FDA Approved: ROPINIROLE HYDROCHLORIDE — Supplemental Application (SOLCO HEALTHCARE US, LLC)
FDA approved a supplemental application for ropinirole hydrochloride from Solco Healthcare US, LLC.